GENOPTIC
Clinical safety rating: caution
Comprehensive clinical and safety monograph for GENOPTIC (GENOPTIC).
Genoptic (gentamicin ophthalmic) is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of mRNA and production of nonfunctional proteins.
| Metabolism | Not appreciably metabolized; excreted unchanged in urine. |
| Excretion | Primarily renal (70-90% unchanged) via glomerular filtration and tubular secretion; biliary/fecal <5%. |
| Half-life | 2-3 hours (prolonged in renal impairment to 18-24 hours); in neonates, 3-8 hours. |
| Protein binding | 20-30% bound to serum albumin. |
| Volume of Distribution | 0.2-0.3 L/kg; low Vd indicates limited tissue distribution (mainly extracellular fluid). |
| Bioavailability | Oral: 60-80% (first-pass effect); ophthalmic: negligible systemic absorption (≤1%). |
| Onset of Action | Intravenous: immediate; oral: 1-2 hours; topical (ophthalmic): 30 minutes. |
| Duration of Action | Intravenous: 6-8 hours; oral: 8-12 hours; topical: 4-6 hours; clinical effect persists while drug levels above MIC. |
Instill 1-2 drops into affected eye(s) every 4-6 hours; for severe infections, every 1-2 hours initially, then reduce frequency as improvement occurs.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No dose adjustment required for ophthalmic use due to minimal systemic absorption. |
| Liver impairment | No dose adjustment required for ophthalmic use due to minimal systemic absorption. |
| Pediatric use | Same as adult dosing: 1-2 drops into affected eye(s) every 4-6 hours; for severe infections, every 1-2 hours initially. |
| Geriatric use | Same as adult dosing; no specific adjustment needed for ophthalmic use. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for GENOPTIC (GENOPTIC).
| Breastfeeding | Unknown if gentamicin is excreted in human milk after topical ophthalmic administration; systemic absorption is low. Caution advised, consider developmental and health benefits of breastfeeding along with mother's clinical need for GENOPTIC. No M/P ratio available. |
| Teratogenic Risk | Category C: No adequate studies in pregnant women. In animal studies, gentamicin (the active ingredient in GENOPTIC) has been associated with fetal renal toxicity and ototoxicity when administered systemically at high doses. Topical ophthalmic use results in minimal systemic absorption, but risk cannot be excluded. Avoid use during first trimester unless clearly needed. |
■ FDA Black Box Warning
Not applicable (no FDA black box warnings for Genoptic).
| Serious Effects |
["Hypersensitivity to gentamicin or any component of the formulation.","History of toxic reactions to aminoglycosides."]
| Precautions | ["Prolonged use may result in overgrowth of nonsusceptible organisms including fungi.","Discontinue use if sensitization or irritation occurs.","Monitor for signs of systemic absorption, especially in patients with renal impairment.","Avoid prolonged use due to risk of secondary infections."] |
Loading safety data…
| Fetal Monitoring | Monitor for signs of hypersensitivity or local irritation. No specific fetal monitoring required with topical ophthalmic use due to minimal systemic absorption. |
| Fertility Effects | No known effect on fertility from topical ophthalmic gentamicin. Systemic aminoglycosides may impair fertility in animal studies at high doses, but clinical relevance for topical use is negligible. |